|
subsections menu :
Contacts
|
Content :
Press releases 2005
December 22, 2005 Sanofi-aventis and Regeneron Pharmaceuticals expand their VEGF Trap oncology collaboration to Japan
December 21, 2005 Sanofi pasteur to license Micro-Delivery technology from BD Medical
December 15, 2005 Sanofi pasteur announces preliminary trial results for a first H5N1 pre-pandemic influenza vaccine candidate with an adjuvant
December 8, 2005 Interim analysis of phase III study shows Taxotere®-based regimens with Herceptin® significantly improved disease free survival in women with early-stage HER2-positive breast cancer
December 2, 2005 FDA grants priority review to Taxotere® for the supplemental new drug application for advanced gastric cancer
November 16, 2005 New England Journal of Medicine publishes the RIO-Lipids study
November 15, 2005 Analysis from several clinical studies show dronedarone appears to be consistently safe and effective in maintaining normal sinusal rhythm and ventricular rate control in patients with cardiac arrhythmia
November 14, 2005 International diabetes survey highlights the differences in disease and treatment perception between people with diabetes and their healthcare providers
November 10, 2005 Sanofi pasteur signs contract with french government to produce pandemic influenza vaccine
November 8, 2005 Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis
October 31, 2005 Sanofi pasteur announces agreement to license novel adjuvant from Eisai Co., Ltd.
October 28, 2005 Pfizer and sanofi-aventis statement on status of EXUBERA®
October 24, 2005 Appointment of Jean-Yves Wessely Senior Vice President, Winthrop
October 14, 2005 EXUBERA® receives positive opinion from CHMP for the treatment of type 1 + type 2 diabetes
October 7, 2005 AMBIEN CR™ now available in the US for the treatment of insomnia
September 29, 2005 Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine HCl) patent infringement case
September 26, 2005 FDA accepts for filing license application for new pediatric combination vaccine, PENTACEL™
September 20, 2005 Microbiological activity of telithromycin against streptococcus pneumoniae shown superior to other standard first line antibiotics over 4-year period
September 19, 2005 Measuring waist circumference: a simple and crucial first step towards tackling heart disease
September 15, 2005 Sanofi pasteur to produce 100 M US Dollars of vaccine against H5N1 influenza virus for U.S. government
September 15, 2005 Interim analysis of phase III study shows TAXOTERE® (docetaxel)- based chemotherapy regimens combined with HERCEPTIN® (trastuzumab) significantly improved disease free survival in early-stage HER2-positive breast cancer
September 14, 2005 Data at EASD suggests better glycaemic control possible using insulin glargine or insulin glulisine in type 2 diabetes
September 13, 2005 Setting of a trial date in the United States PLAVIX® litigation
September 13, 2005 Sanofi-aventis group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl)
September 8, 2005 FDA advisory committee recommends approval of Exubera® for use in adults with type 1 and type 2 diabetes
September 6, 2005 Program evaluating clopidogrel in the prevention of vascular events in atrial fibrillation patients : the ACTIVE trial - Discontinuation of ACTIVE-W arm - ACTIVE-A and ACTIVE-I of the program to continue
September 6, 2005 AMBIEN CR™ (zolpidem tartrate extended-release tablets) Civ receives FDA approval for the treatment of insomnia
August 31, 2005 Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22. Increase in full year adjusted EPS guidance. Positive phase IIb/III results for 6 products
August 18, 2005 Taxotere® Significantly Improves Survival Compared with paclitaxel In Women With Advanced Breast Cancer
August 16, 2005 The U.S. Food and Drug Administration approves Actonel with Calcium®
August 8, 2005 Sanofi-aventis sells its interests in Wacker-Chemie
August 5, 2005 Resolution of UK Plavix® litigation
July 27, 2005 Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers
July 25, 2005 Sanofi pasteur Begins Shipping ADACEL™ Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
July 19, 2005 Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter
July 5, 2005 Transfer of commercial rights of Plavix® in Japan to Sanofi-aventis
June 28, 2005 Panel of experts agree that bone mineral density is no longer enough
June 23, 2005 Safety of the association of Alfuzosin 10 mg OD (Xatral® OD/ Uroxatral®) and Tadalafil 20mg (Cialis®)
June 23, 2005 Rimonabant accepted for filing by the FDA
June 20, 2005 A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show
June 16, 2005 Lovenox® Patent Trial Update
June 14, 2005 Data presented at American Diabetes Association scientific sessions support Exubera® efficacy and safety profile in type 1 and type 2 diabetes
June 13, 2005 Data presented at ADA showed that basal insulin therapy with Lantus® achieved target glycaemic control in poorly controlled type 2 diabetes
June 13, 2005 U.S. FDA Licenses sanofi pasteur’s ADACEL™ Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
June 3, 2005 Statement
June 2, 2005 Sanofi-aventis joins the Paris 2012 “Club des Entreprises” backing the Paris bid to host the 2012 Olympic and Paralympic Games
June 1, 2005 Landmark Taxotere® Study in Early Stage Breast Cancer Published in the New England Journal of Medicine
May 31, 2005 Annual General Meeting
May 24, 2005 New study demonstrates clinical efficacy of telithromycin superior to standard first-line antibiotic therapy for treatment of mild to moderate community-acquired pneumonia (CAP)
May 23, 2005 World Heart Federation and Sanofi-aventis Join Forces to Encourage Prevention of Cardiovascular Disease
May 18, 2005 New study results further enhances the role of Eloxatin® in early and advanced stages of colon cancer
May 15, 2005 Taxotere® regimen demonstrates significant survival benefit in the treatment of advanced gastric cancer
May 13, 2005 2005 first-quarter net sales growth ahead of world pharmaceutical market growth at 11.9% on a comparable basis
May 10, 2005 New Eloxatin® and Taxotere® research to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
May 10, 2005 Rescheduling of the pre-trial order date in the United States Plavix® litigation
April 20, 2005 Lovenox® litigation in the United States
April 15, 2005 Sanofi-aventis affirms its commitment to Access to Medicines in the ''Southern countries'', with a policy of tiered drug prices geared to populations incomes
April 11, 2005 Filing of the form 20-F and 'document de référence'
April 11, 2005 FDA issues approvable letter for AMBIEN CR™ (zolpidem tartrate extended release) for the treatment of insomnia
April 7, 2005 A collaborative agreement between the DNDi foundation and Sanofi-aventis to develop a new, easy-to-use malaria drug at target price below one dollar
April 7, 2005 Statement
April 1, 2005 Sanofi pasteur awarded $97 million HHS contract to accelerate cell-culture pandemic influenza vaccine development
April 1, 2005 Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the Aventis acquisition financing entered into in April 2004
March 31, 2005 Sanofi Pasteur’s New Polio Vaccine Licensed For Use In Novel Approach To Global Eradication Efforts
March 30, 2005 Rescheduling of the pre-trial order date in the United States Plavix® litigation
March 30, 2005 New publication demystifies bone quality and provides a scientific framework to help understand "why bones break"
March 24, 2005 Sanofi-aventis joins the fight against tuberculosis in South Africa
March 22, 2005 Court grants Sanofi-aventis's request for Order of Prohibition in the Canadian Plavix® litigation
March 18, 2005 FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL™ Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
March 17, 2005 Sanofi Pasteur seeks to broaden age group for new vaccine, Menactra™, to protect against meningococcal disease
March 11, 2005 Sanofi-aventis sues Novopharm for patent infringement in Canada
March 9, 2005 Clopidogrel improved coronary perfusion and reduced mortality in acute heart attack
March 2, 2005 Sanofi-aventis and Pfizer seek approval to market Exubera® in the United States
March 1, 2005 Strong growth of 18.2% in 2004 adjusted proforma EPS to 3.89 euros per share
February 24, 2005 Creation of the Sanofi-aventis European Works Council
February 23, 2005 Update of the patent litigation schedule in the United States for Plavix®
February 18, 2005 Erratum: Sanofi-aventis world solidarity day on behalf of South East Asia January 25, 2005: « Sharing in solidarity »
February 18, 2005 Sanofi-aventis world solidarity day on behalf of South East Asia January 25, 2005: « Sharing in solidarity »
February 10, 2005 Appointments at the Communications Department of sanofi-aventis
February 3, 2005 Sanofi-aventis receives FDA approval for new Eloxatin® formulation
January 31, 2005 Two studies demonstrate significant benefit of Eloxatin® - based chemotherapy combined with bevacizumab in advanced colorectal cancer
January 26, 2005 2004 pro forma combined net sales: up 10.0% on a comparable basis
January 25, 2005 Plavix® patent
January 25, 2005 Sanofi-aventis solidarity day in favour of South East Asia
January 19, 2005 Rhodia
January 19, 2005 The european commission imposes a fine on certain MCAA producers
January 11, 2005 Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer
January 10, 2005 Sanofi-aventis and Regeneron Pharmaceuticals reaffirm development commitment
January 10, 2005 Aventis Pasteur, the vaccine division of the Sanofi-aventis Group, changes its name to sanofi pasteur
January 6, 2005 Update of the patent litigation schedule in the United States for Plavix®
January 3, 2005 Sanofi-aventis provides humanitarian aid for South-East Asia
|
Slots : |
Press releases and press packs are intended to journalists, investors and shareholders.
